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Abstract  27 
Muscle anabolic resistance to dietary protein is associated with obesity and insulin resistance. 28 
However, the contribution of excess consumption of fat to anabolic resistance is not well studied. The 29 
aim of these studies was to test the hypothesis that acute and short-term dietary fat overload will 30 
impair the skeletal muscle protein synthetic response to dietary protein ingestion. Eight 31 
overweight/obese males [46.4±1.4 years, BMI 32.3±5.4 kg/m2] participated in the acute feeding study, 32 
which consisted of 2 randomised crossover trials. On each occasion, subjects ingested an oral meal 33 
(with and without fat emulsion) 4h before the coingestion of milk protein, intrinsically labelled with 34 
[1-13C]phenylalanine, and dextrose. Nine overweight/obese males [44.0±1.7 years, BMI 30.1±1.1 35 
kg/m2] participated in the chronic study, which consisted of a baseline 1-week isocaloric diet followed 36 
by a 2-week high fat diet (+25% energy excess). Acutely, incorporation of dietary amino acids into the 37 
skeletal muscle was 2-fold higher (P<0.05) in the lipid trial compared to control. There was no effect 38 
of prior lipid ingestion on indices of insulin sensitivity (muscle glucose uptake, PDC activity and Akt 39 
phosphorylation) in response to the protein/dextrose drink. Fat overfeeding had no effect on muscle 40 
protein synthesis or glucose disposal in response to whey protein ingestion, despite increased muscle 41 
DAG C16:0 (P=0.06) and ceramide C16:0 (P<0.01) levels. Neither acute nor short-term dietary fat 42 
overload has a detrimental effect on skeletal muscle protein synthetic response to dietary protein 43 
ingestion in overweight/obese men, suggesting dietary-induced accumulation of intramuscular lipids 44 
per se is not associated with anabolic resistance. 45 
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Introduction  49 
The inability of skeletal muscle to adequately synthesise new protein in response to anabolic stimuli 50 
such as amino acids (termed ‘anabolic resistance’) is a key contributory factor to the muscle mass loss 51 
observed in a variety of conditions such as ageing, type 2 diabetes (T2D), disuse, and critical illness 52 
(36, 47). Skeletal muscle protein synthesis in response to amino acids appears to be negatively related 53 
to whole body fat mass in obese insulin resistant humans (24). In agreement, overweight and obese 54 
young men exhibit lower postprandial anabolic response to dietary protein ingestion when compared 55 
with healthy lean men (4). It has also been suggested that a sedentary lifestyle and lack of physical 56 
activity may be key parameters in the development of anabolic resistance in obese individuals (29). 57 
Furthermore, skeletal muscles from individuals with higher leg fat mass are more resistant to the 58 
anabolic response of amino acid ingestion in the presence of physiological hyperinsulinaemia when 59 
compared with individuals with lower leg fat mass (33). In support of this, animals studies have shown 60 
the time course of chronic high-fat overfeeding induced obesity and anabolic resistance in rats to 61 
coincide with muscle lipid accumulation (32). Similarly, diet-induced obesity in mice was shown to 62 
impair the activation of skeletal muscle protein synthesis in response to feeding of a mixed meal, 63 
although basal (postabsorptive) rates of skeletal muscle protein synthesis were not affected (2). 64 
Intramuscular accumulation of lipid species has been associated with the inability of skeletal muscle 65 
glucose metabolism to respond adequately to insulin signalling (insulin resistance) (42) (37) (9). 66 
Insulin signalling is also integral to skeletal muscle amino acid delivery, transport and metabolism, in 67 
particular playing a permissive role in the regulation of muscle protein synthesis via activation of the 68 
mammalian (mechanistic) target of rapamycin complex 1 (mTOR) pathway (24, 31). We have 69 
previously shown in healthy young humans that elevating fatty acid availability through an infusion of 70 
heparin plus Intralipid (triglyceride) emulsion in the presence of physiological hyperinsulinaemia 71 
induces insulin resistance and impairs the skeletal muscle fractional protein synthetic rate (FSR) in 72 
response to ingestion of 20 g amino acids (39). This anabolic resistance was mediated in part via the 73 
repression of translation initiation at the level of the eukaryotic initiation factor (eIF) 4E binding 74 




Lipid-induced insulin resistance was observed both at the level of insulin-stimulated glucose disposal 76 
into peripheral tissues and its oxidation at the level of skeletal muscle pyruvate dehydrogenase 77 
complex (PDC) activation (39).  78 
We have recently demonstrated that obese individuals with moderate whole-body glucose intolerance, 79 
insulin resistance and fat distribution in the lower legs do not exhibit a reduced skeletal muscle protein 80 
synthetic response to dietary protein ingestion when compared to lean individuals (29). Thus, it is not 81 
clear whether insulin resistance per se and/or the fat overload and accumulation of intramuscular lipids 82 
are the driving forces for attenuated FSR. Furthermore, there is a paucity of studies investigating the 83 
effects of oral fat overloads rich in saturated fatty acids (SFA) on anabolic resistance, particularly in 84 
overweight/obese individuals. The fatty acid composition of such meals is an important factor, as high 85 
dietary SFA is associated with insulin resistance in humans whereas meals and diets rich in mono- and 86 
poly-unsaturated fatty acids content protect against the development of insulin resistance (27, 44). It 87 
should also be noted that previous studies are either cross-sectional or acute (hours) investigations 88 
performed under insulin clamp conditions, whereas chronic feeding studies are lacking.  89 
The aim of the present studies was to test the hypothesis that both acute and short-term dietary fat 90 
overload (defined as a state of physiologically relevant increase in dietary fat) with primarily saturated 91 
fatty acids under real-life conditions in middle-aged overweight and obese individuals will impair the 92 
skeletal muscle protein synthetic response to dietary protein ingestion.  93 




Subjects and Methods 95 
Acute Feeding Study Subjects. Eight, middle-aged, overweight/obese (n=4 and n=4, respectively) and 96 
physically inactive males [46.4 ± 1.4 years, body mass 96.7 ± 5.3 kg, BMI 32.3 ± 5.4 kg/m2, waist 97 
circumference 107 ± 5 cm, and hip circumference 106 ± 5 cm] were recruited to participate in this 98 
study. The HOMA-IR (fasting glucose x fasting insulin / 22.5), a surrogate index of insulin resistance, 99 
at baseline was 4.7 ± 1.4. 100 
Short-term (overfeeding) Study Subjects. A different group of nine, middle-aged, overweight/obese 101 
(n=3 and n=6, respectively) and physically inactive males [44.0 ± 1.7 years, body mass 97.0 ± 3.3 kg, 102 
BMI 30.1 ± 1.1 kg/m2, waist circumference 106 ± 3 cm, and hip circumference 105 ± 2 cm] were 103 
recruited to participate in this study. The HOMA-IR at baseline was 2.2 ± 0.4.  104 
In both studies, subjects were informed about the nature and risks of the experimental procedures 105 
before their written consent was obtained. The studies were approved by the University of Nottingham 106 
Medical School Research Ethics Committee in observance of the present regulations imposed by the 107 
Code of Ethics of World Medical Association (Declaration of Helsinki). All participants underwent an 108 
individual medical screening, which involved completing health and physical activity questionnaires, 109 
having a 12 lead ECG and blood pressure measured, and a blood sample taken for routine screening. 110 
Individuals with history of cardiovascular disease, diabetes, musculoskeletal disorders, smoking and 111 
excessive alcohol consumption (>28 units per week) were excluded from participation.  112 
Acute Feeding Study - Experimental Protocol. This study was part of a bigger investigation 113 
(ClinicalTrials.gov Identifier NCT03146286). All subjects underwent 2 experimental trials (lasting 7h 114 
each), at least 2 weeks apart, after an overnight fast in a randomised crossover study. On each 115 
occasion, subjects ingested an oral test meal 4 hours before (0h time point) the ingestion of a bolus of 116 
milk protein (0.35 g/kg body mass), which was intrinsically labelled with [1-13C]phenylalanine, along 117 
with 0.8 g/kg body mass of dextrose and 2 g of chocolate powder (containing 0.46 g protein, 0.2 g 118 
CHO, 0.4 g fat) dissolved in 6 ml/kg body mass of water (4h time point). The oral test meal consisted 119 




trial). The oral lipid load consisted of 0.7 g/kg body mass of palm stearin (containing ~65% of 121 
saturated fat), 1g of monoglyceride (emulsifier), 5g of chocolate powder (containing 1.15 g protein, 122 
0.5 g CHO, 1.0 g fat) and 1g of aspartame-based sweetener dissolved in 6 ml/kg body mass of water. 123 
The palm stearin and monoglyceride were excluded from the control drink. The energy content and 124 
macronutrient composition of the two test meals were: Control 0.16 kcal per kg body weight (57.7% 125 
Fat, 29.5% Protein and 12.8% CHO); Lipid 6.22 kcal per kg body weight (98.9% Fat, 0.8% Protein and 126 
0.3% CHO).  127 
 128 
On each occasion, the subjects reported to the laboratory at 08.00 after an overnight fast (10-12h), 129 
having abstained from heavy exercise and alcohol for the previous 48h. Subjects were then asked to 130 
rest on a bed for 7h in a semi-supine position and an intravenous cannula was inserted retrograde into 131 
the superficial hand vein of one arm for arterialised-venous blood sampling. The hand remained in a 132 
hot air warming unit (50-55oC) throughout the trial, with hand and air temperature continuously 133 
monitored (21). The cannula was kept patent via a saline drip. Blood samples were obtained at 134 
baseline (0h) and 1h, 2h, 3h, 3.5h and 4h after ingestion of the test meal for the determination of blood 135 
glucose, insulin, amino acids, free fatty acids (FFA), triglyceride (TAG) and urea concentrations. 136 
Blood samples were also obtained every 15 min after ingestion of the milk protein and dextrose drink 137 
for the determination of plasma phenylalanine, tyrosine and leucine concentrations, and [1-138 
13C]phenylalanine enrichment in addition to the metabolites listed above. Resting energy expenditure, 139 
RER and whole-body substrate oxidation rates were measured using indirect calorimetry for 20 min 140 
before and 2.5h after the ingestion of the milk protein and dextrose drink. Urine samples were 141 
obtained at 0h, 4h and 7h for the determination of nitrogen urea excretion rates, which were used to 142 
correct indirect calorimetry data for protein oxidation rates to allow calculation of non-protein RER 143 
and whole-body substrate oxidation rates using equations from (20). Muscle biopsy samples were 144 
taken before (4h time point) and 3 hours after (7h time point) the ingestion of the milk protein and 145 




protein pool to provide an index of fractional protein synthetic rate (FSR) of dietary protein derived 147 
amino acids (35). 148 
 149 
In order to assess the effect of treatment on local muscle insulin sensitivity, on 2 separate subsequent 150 
occasions, 5 of the 8 subjects [46.4 ± 1.4 years, body mass 96.7 ± 5.3 kg, BMI 32.3 ± 5.4 kg/m2, waist 151 
circumference 107 ± 5 cm, and hip circumference 106 ± 5 cm] repeated the 2 acute trials (without 152 
undergoing skeletal muscle biopsies) and had 2 intravenous cannulae inserted retrograde into a 153 
superficial hand vein of one arm for arterialized-venous blood sampling and into a deep antecubital 154 
vein of the other arm for deep venous blood sampling using ultrasound guidance. As above, the hand 155 
remained in a hot air warming unit (50-55oC) throughout the trial. Blood samples from each sampling 156 
line were obtained at the same intervals described above for the determination of blood glucose 157 
concentrations. Differences between arterialised venous (from the hand) and deep venous (from the 158 
antecubital vein) glucose concentrations, along with measurements of blood flow of the brachial artery 159 
(BFBA; expressed in ml∙min-1) using Doppler ultrasound, were used to determine rates of glucose (G) 160 
uptake (expressed in µmol∙l-1) across the forearm using the following equation: Guptake = ([G]arterialised - 161 
[G]venous) × BFBA. This provided an index of local muscle insulin sensitivity.  162 
Short-term (overfeeding) Study – Experimental Protocol. All subjects consumed an isoenergetic diet 163 
that matched their habitual total daily energy expenditure for 1 week (baseline isocaloric phase; 164 
approx. 35%E fat, 47.5%E CHO and 17.5%E protein) before attending their first main experimental 165 
visit. All food was provided for the participants via a delivery to their home or collection from the 166 
laboratory. The energy intake for each subject was based on their habitual food intake as determined 167 
using 3-day food diaries and matched to the individual’s predicted total energy expenditure using the 168 
Henry Equation (25) and a self-administered IPAQ questionnaire (15). Following the first 169 
experimental visit, each subject continued to receive the same diet but with +25% energy excess 170 
energy from fat (48-50%E fat, 37%E CHO and 13%-15%E protein) for 2 weeks (fat overfeeding 171 
phase) before returning for the second experimental visit. Subjects received the 25% excess calories 172 
during the overfeeding phase in the form of double cream (Sainsbury’s, UK: 100ml: 47.5g fat, 2.6g 173 





On each experimental visit, the subjects reported to the laboratory at 08.00 after an overnight fast (10-176 
12h), having abstained from heavy exercise and alcohol for the previous 48h, and rested in a semi-177 
supine position while cannulae were inserted into a superficial dorsal hand vein for arterialized-venous 178 
blood sampling and in both forearm veins (antecubital fossa) for insulin, glucose and stable isotope 179 
infusions. Baseline blood samples were obtained for the determination of blood glucose, insulin and 180 
FFA concentrations. A 360-min primed (4mg/kg), continuous infusion of [6,62H2] glucose 181 
(40µg/kg/min) was then initiated for the determination of glucose appearance (Ra) and glucose 182 
disappearance (Rd) rates. Phenylalanine (L-[ring-2H5]-phenylalanine) was also infused at 0.5/kg/hr for 183 
360 min for the determination of skeletal muscle FSR. After the first 120 min of tracer infusion, a 184 
hyperinsulinaemic (30mU/m2/min) euglycaemic clamp was commenced for the next 150 min, at which 185 
point (270 min from the start of the tracer infusion) a 25 g whey protein isolate drink spiked with 6% 186 
[2H5]phenylalanine was ingested (MyProtein, UK). The insulin clamp was continued for a further 90 187 
min until the end of the 360 min infusion period. The period between 120-270 min was used to assess 188 
the effect of overfeeding on skeletal muscle insulin sensitivity, whereas the period between 270-360 189 
min was used to assess the effect of treatment on muscle FSR. Muscle biopsy samples were taken 190 
before (270 min time point) and after (360 min time point) the ingestion of the whey protein drink in 191 
order to assess changes in the activation (phosphorylation) of key signaling proteins and measure 192 
[2H5]phenylalanine incorporation into the muscle protein pool. 193 
 194 
Arterialised blood samples were obtained from the heated hand vein every 60 min for the first 120 min 195 
and every 30 min during the insulin clamp to determine plasma [6,62H2] glucose enrichment. Further 196 
blood samples were taken every 5 min during the insulin clamp for the determination of glucose 197 
concentrations, and every 30 min over the entire period of infusion for the determination of serum 198 
insulin and plasma FFA concentrations. Resting energy expenditure and whole-body substrate 199 
oxidation rates were measured using indirect calorimetry for 15 min before the infusion of the tracer 200 





Blood and Urine Analysis. In both studies, whole blood glucose concentrations were determined 203 
using a Yellow Springs Instrument Analyzer (YSI, 2300 STAT PLUS). Serum was separated from one 204 
aliquot of blood by centrifugation (15 min at 3,000 g) after being allowed to clot and analyzed for 205 
insulin concentrations by radioimmunoassay (HI014K, Merk Millipore, MA, US) and TAG 206 
concentrations by coupled enzymatic colorimetry using a clinical chemistry analyser (ABX Pentra 207 
400, Horiba Ltd., Kyoto, JP). Another aliquot of blood was collected into a tube containing 30µl 208 
EGTA glutathione and centrifuged immediately at 3,000g for 15 min at 4oC to obtain plasma that was 209 
aliquoted into a tube containing tetrahydrolipostatin (30 μg/ml plasma) for the dermination of FFA 210 
using a commercially available kit (NEFA HR-2, Wako, Osaka, JPN). In the acute feeding study, 211 
urinary and plasma urea concentrations were determined using a commercially available enzymatic 212 
kinetic assay (Randox Cat# UR220). In both studies, after deproteinisation on ice with dry 5-213 
sulfosalicylic acid, another aliquot of plasma separated from EGTA treated blood was also analysed 214 
for phenylalanine, tyrosine and leucine concentrations, and [1-13C]phenylalanine enrichment (acute 215 
feeding study) and L-[ring-2H5 ]-phenylalanine enrichment (short-term overfeeding study) by GC-MS 216 
(Agilent 7890A GC/5975C; MSD, Little Falls, DE) after derivitisation with tert-butyl dimethylsilyl 217 
(TBDMS) as previously described (11, 22).  218 
 219 
Skeletal muscle biopsy and analysis. Muscle biopsies were obtained from the middle region of the 220 
vastus lateralis muscle using the percutaneous needle biopsy technique as described previously (5). In 221 
a given trial, muscle biopsies were taken from the same leg spaced by at least 3 cm. Muscle biopsies 222 
were rapidly frozen in liquid nitrogen cooled isopentane and stored in liquid nitrogen for subsequent 223 
analysis. 224 
 225 
One portion of the frozen muscle sample (~50 mg) was freeze-dried, separated free of visible blood 226 
and fat, and following ice-cold 2% perchloric acid extraction, analysed for intracellular tissue [1-227 
13C]phenylalanine (acute feeding study) and L-[ring-2H5 ]-phenylalanine (short-term overfeeding 228 
study) incorporation into the myofibrillar protein pool (acute study) and muscle mixed protein pool 229 




from the remaining protein pellet as described previously (22) and used to determine the [1-231 
13C]phenylalanine or L-[ring-2H5 ]-phenylalanine enrichment using GC-MS.  232 
 233 
In the acute study, muscle BCAA and their keto acids and short-chain acylcarnitines were analysed 234 
using both hydrophilic interaction liquid chromatography (leucine, isoleucine and valine) and reversed 235 
phase chromatography (KIC, KMV and KV) coupled to high resolution mass spectrometry. A single 236 
extraction procedure using a mixture of isopropanol and acetonitrile containing isotopically labelled 237 
internal standard for each metabolite of interest was used. Method validation in skeletal muscle and a 238 
proxy matrix (7.5% BSA) showed excellent linearity (R2 > 0.99), accuracy and precision, and 239 
consistent levels of recovery across all metabolites. 240 
 241 
Western blotting. In both studies, total muscle protein homogenates were extracted from another 242 
portion (~30 mg) of the frozen muscle tissue by homogenisation in a HEPES phosphatase buffer in the 243 
presence of protease and phosphatase inhibitors (P-8340, Sigma, UK) as described previously (42). 244 
Protein was quantified using the bicinchonic acid (BCA) protein (Pierce, Perbio, Aalst, Belgium). The 245 
muscle protein content of phosphorylated Akt (serine473, 1:500, Cat. No #9271), mTOR (serine2448, 246 
1:1000, Cat. No #2971), 4E-BP1 (threonine37/46, 1:500, Cat. No #9459) (all by Cell Signalling, 247 
Beverly, MA USA) and Actin (1:5000, Cat. No #A2066, Sigma, Dorset, UK) were determined by 248 
western blot analysis using an anti-rabbit horseradish peroxidase (1:2000, Cat. No #P0217, Dako, 249 
Denmark) as a secondary antibody. All immunoreactive proteins were visualized using Amersham™ 250 
ECL™ Prime Western blotting detection reagent (GE Healthcare Life Sciences, Buckinghamshire, 251 
UK), quantified by densitometry using the Quantity One 1-D Analysis Software version 4.5 (Bio-Rad 252 
Laboratories, Inc., USA), and normalized to α-actin (Sigma-Aldrich Company Ltd., Dorset, UK). 253 
  254 
Muscle lipid content. In both studies, intramyocellular lipid (IMCL) content, lipid droplet size and 255 
number analysis was performed as previously described (12, 43). In the chronic (overfeeding) study, 256 




ceramide (C16:0, C18:0, C24:0) species was performed in 5 mg freeze-dried muscle powder using 258 
high-performance liquid chromatography tandem mass spectroscopy as previously described (7, 8, 259 
12).  260 
 261 
Calculations. In the short-term overfeeding study, calculations of glucose disposal were made at 262 
steady state during the insulin clamp (210-270 min period). The modified Steele equations (19) were 263 
used to calculate glucose appearance Ra during basal (0-120 min) and insulin stimulated (120-270 264 
min) states. Hepatic glucose output (HGO) was calculated as the difference between Ra and glucose 265 
infusion rate (GIR) during the clamp and, therefore, total rate of glucose disappearance (Rd), the true 266 
measure of glucose disposal, was calculated as the sum of HGO and GIR. 267 
 268 
Skeletal muscle FSR was calculated by dividing the increment in enrichment in the product (i.e., 269 
protein-bound [ring-2H5]phenylalanine) by the enrichment of the precursor. Plasma and muscle free 270 
[ring-2H5]phenylalanine enrichments were used to provide an estimate of the lower and higher 271 
boundaries of true FSR, respectively. The formula used was FSR = [ΔEp/(Eprecursor × t)] × 100, 272 
where ΔEp is the delta increment of protein-bound [ring-2H5]phenylalanine during incorporation 273 
periods, Eprecursor is the enrichment of the precursor used during the time period for amino acid 274 
incorporation determination, and t denotes the time duration (h) between biopsies. Data were then 275 
multiplied by 100 to express FSR as percentage per hour. 276 
 277 
Statistical analysis. Data analysis was carried out using GraphPad Prism 7.0 Software (GraphPad 278 
Software Inc., San Diego, CA). All blood and muscle data were analysed using a two-way (treatment x 279 
sampling time) analysis of variance (ANOVA). When a significant difference was obtained with the 280 
two-way ANOVA, data were further analysed with Student’s paired t-tests using the Bonferroni 281 
correction. [13C]phenylalanine incorporation into the myofibrillar protein pool was assessed using a 282 







Acute Feeding Study. 287 
Blood glucose, serum insulin, serum TAG and plasma FFA. Blood glucose and serum insulin 288 
concentrations were similar between trials at baseline and during the first 4h following the ingestion of 289 
the test meal (Figure 1A and 1B). Although circulating glucose and insulin increased (time effect 290 
P<0.0001) in response to milk protein and dextrose ingestion at 4h, there were no differences between 291 
trials at any time point during the last 3h.  292 
Two-way ANOVA revealed significant interaction effects (P<0.0001) between trials (control vs. lipid) 293 
and time (baseline vs. postprandial sampling times) for serum TAG and plasma FFA levels (Figure 294 
1C and 1D). Specifically, serum TAG increased in response to the ingestion of the fat test meal and 295 
decreased after the ingestion of the milk protein and dextrose solution, whereas values remained 296 
unchanged throughout the control trial. As a result, serum TAG concentrations were higher at 2h, 3h, 297 
3.5h and 4h following ingestion of the fat test meal and for the first 105 min after ingestion of the milk 298 
protein and dextrose solution when compared to the control meal (Figure 1C). Plasma FFA 299 
concentrations increased (P<0.001) between 3h and 4h after ingestion of the fat test meal and were 300 
higher at 4h when compared with control (P<0.01), whereas a smaller but significant increase from 301 
baseline was also observed in the control trial at 4h (P<0.01). However, the suppression of the FFA 302 
observed in both trials following ingestion of the milk protein and dextrose solution at 4h was 303 
attenuated in the lipid trial such that values were higher (P<0.001) for the next 90 min (between 4h-304 
5.5h) when compared with control (Figure 1D).   305 
RER and whole-body substrate oxidation rates. Non-protein RER tended to be lower (treatment 306 
effect P=0.06) in the lipid trial when compared to control both 4h after ingestion of the test meal (0.75 307 
± 0.01 and 0.80 ± 0.02, respectively) and 3h after ingestion of the milk protein plus dextrose solution 308 
(0.79 ± 0.01 and 0.83 ± 0.02, respectively) (Figure 1E). As a result, fat oxidation rates were higher 309 




Forearm glucose uptake. There was no effect of treatment (Control vs. Lipid) on postprandial 311 
concentrations of glucose in arterialised or deep venous blood in response to feeding of the milk 312 
protein plus dextrose solution, and thus no significant differences between trials were found in glucose 313 
uptake across the forearm tissue (Figure 1F). 314 
Plasma amino acids. Two-way ANOVA revealed a significant treatment effect for plasma leucine 315 
(P<0.001) and a trend for phenylalanine (P=0.054) concentrations. Both amino acids were unchanged 316 
during the first 4h following ingestion of the test meal in the control and lipid trials (Figure 2A and 317 
2B) but, following the ingestion of the milk protein plus dextrose solution, the increase in their levels 318 
was attenuated in the lipid trial. On the other hand, two-way ANOVA revealed a trend for an 319 
interaction effect (P=0.058) in plasma tyrosine levels, which declined at 3.5h and 4h after ingestion of 320 
the lipid but not control test meal. Following the ingestion of the milk protein plus dextrose solution, 321 
plasma tyrosine levels increased in both trials but this effect was attenuated in the lipid trial (Figure 322 
2C). 323 
Plasma enrichment of [1-13C]phenylalanine and incorporation into muscle protein. Plasma [1-324 
13C]phenylalanine enrichment (MPE) was negligible at baseline and during the first 4h after ingestion 325 
of the test meal but increased in both trials following the ingestion of the intrinsically labelled milk 326 
protein (time effect P<0.0001) and reached a plateau after 90 min. However, there was no difference 327 
in the enrichment between trials (Figure 2D). Skeletal muscle [1-13C]phenylalanine tracer to tracee 328 
ratio (TTR), reflecting the incorporation of dietary protein derived amino acids into the skeletal muscle 329 
myofibrillar protein pool, was 2-fold higher (P<0.05) in the lipid trial when compared to control 330 
(Figure 2E). 331 
Muscle BCAA, keto acid and short-chain acylcarnitine content. There was a strong trend for 332 
intramuscular leucine (interaction effect P=0.06), isoleucine (interaction effect P=0.08) and valine 333 
(interaction effect P=0.06) content and their sum (interaction effect P=0.06) to be lower in the lipid 334 
trial (Figure 3A-D). Accordingly, their respective keto acids KIC (treatment effect P<0.01), KMV 335 




P<0.01) was also lower in the lipid trial when compared with control (Figure 3E-H). Furthermore, the 337 
sum of BCAA-derived short-chain acylcarnitines (C3, C5 and ISOC5), which provides an index of 338 
BCCA oxidative flux, tended to be lower (interaction effect P=0.069; n=7) in the lipid trial (0 min: 339 
20.3 ± 3.5 μmol/kg dm; 180 min: 14.8 ± 1.9 μmol/kg dm) when compared to control (0 min: 16.8 ± 340 
2.1 μmol/kg dm; 180 min: 21.6 ± 4.4 μmol/kg dm). 341 
Muscle IMCL content. The IMCL content (% area of muscle fibre analysed) was similar between 342 
trials and remained unchanged in response to the ingestion of test meal and the intrinsically labelled 343 
milk protein plus dextrose solution (Figure 2F).  344 
Muscle PDC and signalling proteins. Muscle PDC activity was unchanged in response to the 345 
ingestion of test meal and the intrinsically labelled milk protein plus dextrose solution, with no 346 
differences observed between trials (Figure 4A). Muscle Akt phosphorylation at serine473 was similar 347 
between trials 4h after ingestion of the test meal and increased to a similar degree after the ingestion of 348 
the milk protein plus dextrose solution (time effect P<0.01) (Figure 4B). Muscle mTOR 349 
phosphorylation at serine2448 (Figure 4C) also increased after the ingestion of the milk protein plus 350 
dextrose solution although there was a trend for it to be higher during the lipid trial when compared 351 
with control (time effect P<0.05 and treatment effect P=0.10). However, muscle p4EBP1 352 
phosphorylation at threonine37/46 was unchanged in response to the ingestion of test meal and the 353 
intrinsically labelled milk protein plus dextrose solution, with no differences observed between trials 354 
(Figure 4D). 355 
Short-term (fat overfeeding) Study. 356 
Body mass and BMI. The overfeeding period increased body mass (from 97.0 ± 3.3 to 97.7 ± 3.1 kg, 357 
P<0.01) and BMI (from 30.1 ± 1.1 to 30.4 ± 1.1 kg/m2, P<0.05). 358 
Changes in fasting markers of insulin sensitivity and lipid markers. There was no effect of 359 
overfeeding on fasting levels of blood glucose, insulin or HOMA-IR (all markers of fasting insulin 360 
sensitivity) following two weeks of overfeeding (Table 1). There was also no effect of overfeeding on 361 





IMCL accumulation. Two weeks of fat overfeeding did not affect IMCL content in mixed skeletal 364 
muscle. In particular, there was no difference between isocaloric and fat overfeeding diets in percent 365 
total coverage of lipid droplets or lipid present in the subsarcolemmal and intermyofibrillar regions 366 
(Table 2). Furthermore, there was no effect of fat overfeeding in lipid droplet size or the number of 367 
lipid droplets per fibre.  368 
 369 
Muscle DAGs and ceramides. Following the 2-week fat overfeeding period, there was a trend for an 370 
increase in C16:0 DAG (P = 0.06), although there were no changes in either C16:0/C18:1 or C18:1 371 
DAG (Figure 5A-C). However, there was a significant increase in C16:0 (P < 0.01) but not C18:0 or 372 
C24:0 ceramide species (Figure 5D-F).  373 
Insulin sensitivity and muscle protein synthesis. When comparing the steady state phase between 374 
120-270 min, the 2-week fat overfeeding period resulted in similar glucose rate of disappearance (Rd) 375 
during the insulin clamp prior to protein ingestion. The consumption of protein caused an increase in 376 
glucose Rd both after the isocaloric and the fat overfeeding periods (time effect P<0.001). (Figure 377 
6A). There was no difference in serum insulin concentrations during the steady-state phase of the 378 
insulin clamp before protein feeding between trials (Figure 6B). Serum insulin concentrations 379 
increased following the ingestion of protein (time effect P<0.0001) but there was no difference 380 
between the isocaloric and fat overfeeding periods (Figure 6B).   381 
Mixed-muscle FSR in response to the protein drink (270-360min) was not affected by the overfeeding 382 
intervention (Figure 6C). Similarly, there was no significant difference in FSR during the 383 
hyperinsulinaemic clamp before the ingestion of the protein drink following the 2-week fat 384 
overfeeding period (Figure 6C).  385 
Plasma phenylalanine. There was no significant difference in fasting plasma phenylalanine levels 386 
after fat overfeeding in comparison to the isocaloric condition (50.7 ± 4.2 vs. 52.7 ± 3.3 μmol/l, 387 
respectively). Plasma phenylalanine levels increased after protein ingestion after both the isocaloric 388 




at 360 min. Moreover, when plasma phenylalanine was calculated as molar percent excess (MPE) 390 
there was no significant difference between the isocaloric and overfeeding conditions (area under the 391 
curve: 2548 ± 82 vs. 2509 ± 75, respectively). 392 
Muscle p4E-BP1. There was no significant difference in p4E-BP1 (threonine37/46) phosphorylation 393 
before or after protein ingestion. However, p4E-BP1 (threonine37/46) significantly increased following 394 
overfeeding after protein ingestion when compared with the isocaloric diet (overfeeding effect P < 395 
0.05) (Figure 7).   396 
 397 




Discussion  399 
The main finding from these studies was that neither acute nor short-term dietary fat overload with 400 
primarily saturated fatty acids in middle-aged overweight/obese individuals had a detrimental effect on 401 
skeletal muscle protein synthetic response to dietary protein ingestion. Surprisingly, acute lipid 402 
feeding resulted in a two-fold increase in the incorporation of dietary [1-13C]phenylalanine into the 403 
muscle myofibrillar protein pool, representing the uptake and incorporation of dietary protein derived 404 
amino acids in the myofibrillar protein pool.   405 
This increase in muscle protein synthesis occurred in the absence of lipid-induced changes in muscle 406 
CHO metabolism and insulin sensitivity as indicated by similar muscle glucose uptake, PDC activity 407 
and Akt phosphorylation responses to the intrinsically labelled milk protein and dextrose solution 408 
between the acute control and lipid trials. This finding supports our previous premise that insulin 409 
resistance may be required to induce anabolic resistance under conditions of acute lipid overload in 410 
humans (39). In the latter study, the inability of skeletal muscle to increase protein synthesis in 411 
response to insulin and amino acid administration under conditions of elevated lipid availability 412 
appeared to be mediated, at least in part, via the repression of translation initiation at the level of 4E-413 
BP1 but was independent of the phosphorylation of mTOR. The sensitivity of  4E-BP1 to elevated 414 
lipid availability was corroborated in a recent study that showed an attenuated phosphorylation of 4E-415 
BP1 in response to 5 hours infusion of a lipid emulsion (intralipid) that elevated circulating FFA levels 416 
by ~4-fold in middle-aged, overweight individuals (38). In contrast, in the present study there was no 417 
difference in muscle p4EBP1 phosphorylation at threonine37/46 between trials, although muscle mTOR 418 
phosphorylation at serine2448 tended to be higher during the lipid trial when compared with control, 419 
indicating that lipid-induced activation of mTOR might be involved in the increase in muscle protein 420 
synthesis following acute lipid feeding. Amino acids and insulin promote the activation of the mTOR 421 
pathway leading to increased protein synthesis through the regulation of mRNA translation (3). In 422 
C2C12 myotubes, palmitate has been shown to induce the mTORC1/p70S6K pathway through a 423 
decrease in raptor (regulatory-associated protein of mammalian target of mTOR) phosphorylation 424 




pathway is also involved in SFA-induced insulin resistance, and chronically activated or aberrant 426 
mTORC1 signalling in obese skeletal muscle attenuates its response to insulin and amino acids (17).  427 
In the present study, the attenuated levels of plasma AA (leucine, tyrosine and phenylalanine) in the 428 
lipid trial may suggest a delayed appearance in the circulation. Indeed, carbohydrate (a mixture of 429 
dextrose and maltodextrin) coingestion with protein was previously shown to delay dietary protein 430 
digestion and absorption (as indicated by delayed appearance of exogenous labelled phenylalanine in 431 
the circulation) without affecting postprandial muscle protein synthesis (22). The fact that plasma 432 
enrichment of [1-13C]phenylalanine was similar between trials in the present study, suggests that 433 
ingestion of dietary lipids several hours before the coingestion of protein and dextrose may enhance 434 
the uptake of AA into skeletal muscle of overweight/obese individuals (rather than delay their 435 
appearance in the circulation) and hence facilitate their subsequent availability for augmentation of 436 
protein synthesis. The fact that muscle BCAA (leucine, isoleucine and valine) concentrations, their 437 
respective ketoacids and short-chain acylcarnitines, an index of BCCA oxidative flux, were also lower 438 
in the lipid trial, when compared with control, further supports the notion of enhanced redirection of 439 
intramuscular free AA towards incorporation into the muscle myofibrillar protein pool (as indicated by 440 
increased FSR in the present study) rather than oxidative catabolism. Indeed, it has previously been 441 
shown in animal models that elevated FFA availability via infusion of triglycerides results in protein 442 
sparing via reductions in whole-body leucine flux and oxidation (41). Although muscle protein 443 
breakdown was not assessed in the present study, in postabsorptive humans elevated levels of 444 
circulating FFA via infusion of lipid emulsions were previously shown to inhibit release of muscle AA 445 
and muscle protein breakdown (23, 45, 48).  446 
Although our findings are in agreement with the study by Katsanos et al  (28),  they are in contrast to a 447 
recent study that showed an attenuated muscle protein synthetic response to whey protein ingestion 448 
during a 5-hour infusion of a lipid emulsion (intralipid) that elevated circulating FFA levels by ~4-449 
fold, when compared with saline infusion, in middle-aged overweight individuals (38). Although there 450 
was no concurrent infusion of insulin or coningestion with CHO (which precluded assessment of 451 




supraphysiological circulating concentrations of FFA have previously been associated with profound 453 
development of both insulin resistance (40, 42) and anabolic resistance (39). However, in the current 454 
study we used dietary fat overload to acutely elevate circualting FFA to more modest levels, typically 455 
observed during the postprandial period in humans, and coingested milk protein with dextrose to 456 
maximise the insulin reponse and provide a real-life metabolic mileu for our observations. These 457 
methodological differences may explain the apparent discrepancies in muscle protein sythetic reponses 458 
to dietary amino acids between those studies under conditions of acutely elevated fat availability in 459 
humans.       460 
Since neither insulin resistance nor accumulation of intramuscular lipids was observed in the acute 461 
lipid overload study, we tested the hypothesis that more prolonged dietary lipid overload may be 462 
required to induce accumulation of intramuscular lipids and attenuate FSR in overweight/obese 463 
individuals. Although two weeks of overfeeding with a diet rich in SFA successfully increased body 464 
mass by around 1kg, it did not affect total IMCL content in mixed skeletal muscle. However, 465 
overfeeding increased skeletal muscle DAG levels along with its ceramide species. In contrast to that 466 
reported previously (1, 12, 26), the increase in muscle DAG and ceramide levels were not associated 467 
with the development of insulin resistance, as indicated by unchanged fasting HOMA-IR and glucose 468 
Rd during the hyperinsulinaemic euglycaemic clamp both in the absence and presence of oral protein 469 
ingestion. Interestingly, although the subjects in the overfeeding study had lower fasting HOMA 470 
values than the subjects in the acute study, their relatively low insulin-stimulated glucose disposal 471 
rates during the insulin clamp indicate some degree of muscle insulin resistance prior to the 472 
intervention (14). Perhaps longer high fat feeding periods may have been required to induce further 473 
skeletal muscle insulin resistance at the level of glucose disposal in humans, which is preceded by 474 
altered intracellular partitioning of glucose metabolism leading to decreased oxidation and increased 475 
non-oxidative glucose disposal (6, 13, 16). Interestingly, fat overfeeding did not attenuate mixed-476 
muscle FSR in response to the oral protein drink, which suggests that accumulation of intramuscular 477 
lipids is not the driving force for the attenuated FSR observed in previous studies under conditions of 478 




course of chronic high-fat overfeeding induced obesity and anabolic resistance coincides with muscle 480 
lipid accumulation (32), but supported by studies showing that diet-induced obesity via high fat 481 
feeding in mice can induce insulin resistance after 3 weeks (34) and impair the activation of skeletal 482 
muscle protein synthesis in response to feeding of a mixed meal after 9 weeks (2). Moreover, in 483 
contrast to other studies where lipid induced anabolic resistance was associated with supressed muscle 484 
4E-BP1 phosphorylation (38, 39), two weeks of high fat overfeeding increased p4E-BP1 in the present 485 
study, perhaps as a result of increased energy content of the diet per se. Taken together, it would 486 
appear that overt insulin resistance must be present to observe a blunted anabolic response to protein 487 
ingestion in obese individuals. Interestingly, physical inactivity or disuse also impairs the anabolic 488 
response to protein ingestion (10, 46), and can induce severe insulin resistance (18). Therefore, 489 
differences in habitual physical activity levels may, at least in part, explain the apparent discrepancy in 490 
the published literature regarding the impact of obesity on postprandial anabolic resistance (4, 29). 491 
 492 
In conclusion, neither acute nor short-term dietary fat overload with primarily saturated fatty acids in 493 
middle-aged overweight/obese individuals have a detrimental effect on skeletal muscle protein 494 
synthetic response to dietary protein ingestion. In the absence of insulin resistance, dietary-induced 495 
accumulation of intramuscular lipids is not associated with anabolic resistance to dietary protein 496 
ingestion per se, and it appears that FFA availability may retain its protein sparing ability in middle-497 
aged obese individuals. These findings have important implications for maintenance of muscle mass 498 
and its relationship to lipid-induced insulin resistance in obesity and ageing as alterations in muscle 499 
protein turnover play an important role in age-related decline in skeletal muscle mass (sarcopenia), 500 
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Figure legends 668 
Figure 1. Effect of an oral test drink consisting of either a fat emulsion (lipid trial) or water (control 669 
trial), ingested 4 hours before the ingestion of a bolus of CHO (dextrose) and intrinsically labelled 670 
milk protein drink, on (A) arterialized blood glucose concentration (mmol/l), (B) arterialized serum 671 
insulin concentration (mU/l), (C) arterialized plasma FFA concentration (mmol/l), (D) arterialized 672 
serum TAG concentration (mmol/l), (E) non-protein RER, and (F) forearm glucose uptake 673 
(μmol/min), before (0 min), during and 180 min after the ingestion of the CHO and milk protein drink. 674 
Data are means ± SEM; n = 8 for all variables except for glucose uptake (n=5). 675 
Figure 2. Effect of an oral test drink consisting of either a fat emulsion (lipid trial) or water (control 676 
trial), ingested 4 hours before the ingestion of a bolus of CHO (dextrose) and intrinsically labelled 677 
milk protein drink, on (A) arterialized plasma leucine concentration (μmol/l), (B) arterialized plasma 678 
phenylalanine concentration (μmol/l), (C) arterialized plasma tyrosine concentration (μmol/l), (D) 679 
arterialized plasma [1-13C]phenylalanine enrichment (MPE), (E) skeletal muscle [1-13C]phenylalanine 680 
TTR, and (F) IMCL content (% area of muscle fibre analysed), before (0 min), during and 180 min 681 
after the ingestion of the CHO and milk protein drink. Data are means ± SEM; n=8 for all variables 682 
except for IMCL (n=5); *p < 0.05 from Control. 683 
Figure 3. Effect of an oral test drink, consisting of either a fat emulsion (lipid trial) or water (control 684 
trial), ingested 4 hours before the ingestion of a bolus of CHO (dextrose) and intrinsically labelled 685 
milk protein drink, on (A) muscle leucine concentration (μmol/kg dm), (B) muscle isoleucine 686 
concentration (μmol/kg dm),  (C) muscle valine concentration (μmol/kg dm), (D) sum of muscle 687 
BCCA (leucine, isoleucine and valine) concentrations (μmol/kg dm), (E) muscle KIC concentration 688 
(μmol/kg dm), (F) muscle KMV concentration (μmol/kg dm), (G) muscle KIV concentration 689 
(μmol/kg dm), and (H) sum of muscle ketoacid (KIC, KMV and KIV) concentrations (μmol/kg dm), 690 
before (0 min) and 180 min after the ingestion of the CHO and milk protein drink. Data are means ± 691 
SEM; n=7 for all variables; *p < 0.05 from Control; **p < 0.01 from Control (based on post hoc 692 




Figure 4. Effect of an oral test drink consisting of either a fat emulsion (lipid trial) or water (control 694 
trial), ingested 4 hours before the ingestion of a bolus of CHO (dextrose) and intrinsically labelled 695 
milk protein drink, on (A) muscle PDC activity (mmol acetylCoA/kg dm/min), (B) muscle Akt 696 
phosphorylation at serine473 (normalized to α-actin content), (C) muscle mTOR phsosphorylation at 697 
serine2448 (normalized to α-actin content), and (D) muscle 4E-BP1 phsosphorylation at threonine37/46 698 
(normalized to α-actin content), before (0 min) and 180 min after the ingestion of the CHO and milk 699 
protein drink. Data are means ± SEM; n=8 for all variables.  700 
Figure 5. Effect of fat overfeeding or isocaloric diet on overnight fasted values of (A) muscle DAG 701 
C16:0 concentration (μmol/kg dm), (B) muscle DAG C16:0/C18:1 concentration (μmol/kg dm), (C) 702 
muscle DAG C18:1 concentration (μmol/kg dm), (D) muscle ceramide C16:0 concentration (μmol/kg 703 
dm), (E) muscle ceramide C18:0 concentration (μmol/kg dm), and (F) muscle ceramide C24:0 704 
concentration (μmol/kg dm). Data are means ± SEM; n=7 for all variables; **p<0.01 from isocaloric 705 
diet. 706 
Figure 6. Effect of fat overfeeding or isocaloric diet on (A) glucose rate of disappearance (Rd) 707 
(mg/kg/min), (B) serum insulin concentration (mU/l), (C) muscle FSR (%/h), and (D) plasma 708 
phenylalanine concentration (μmol/l), during an insulin clamp before (Insulin) and after the ingestion 709 
of an oral protein drink (Insulin+ Protein). Data are means ± SEM; n=9 for glucose Rd and serum 710 
insulin; n=8 for muscle FSR and plasma phenylalanine; ***p<0.001 from respective Insulin, 711 
****p<0.0001 from respective Basal (based on post hoc analysis).  712 
Figure 7. Effect of fat overfeeding or isocaloric diet on muscle 4E-BP1 phsosphorylation at 713 
threonine37/46 (normalized to α-actin content). Data are means ± SEM; n=6.  714 
 715 
Table 1. Fasting insulin sensitivity and lipid makers after isocaloric and fat overfeeding  
diets. 
 Isocaloric Fat overfeeding 
Fasting glucose (mmol/l) 4.8 ± 0.2 4.7 ± 0.2 
Fasting serum insulin (mU/l) 10.1 ± 1.9 12.5 ± 3.2 
HOMA-IR 2.2 ± 0.4 2.7 ± 0.7 
TAG (mmol/l) 1.42 ± 0.24 1.47 ± 0.17 
FFA (mmol/l) 0.43 ± 0.05 0.44 ± 0.04 
Cholesterol (mmol/l) 5.17 ± 0.38 5.48 ± 0.44 
HDL (mmol/l) 1.03 ± 0.04 1.09 ± 0.08 
LDL (mmol/l) 3.47 ± 0.36 3.72 ± 0.40 




    Table 2. IMCL after isocaloric and fat overfeeding diets.  
 Isocaloric Fat overfeeding 
% Lipid coverage 3.16 ± 0.27 3.21 ± 0.27 
SSL LD (% fibre area) 2.61 ± 0.25 2.69 ± 0.24 
IMF LD (% fibre area) 0.55 ± 0.07 0.53 ± 0.06 
LD per fibre       56.3 ± 8.1      45.3 ± 5.9 
LD size (μm2) 0.46 ± 0.01 0.47 ± 0.01 
All values are mean ± SEM; n = 9. Abbreviations:  






















































































































































































































































































































































































































































































































































































Treatment effect  P<0.05
























Treatment effect  P<0.05






















Interaction effect  P<0.05





















































































































































































































































































































































































Time effect  P<0.0001
*******























































Overfeeding effect  P<0.05
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